Skip to main content

MECANISMOS DE MIELINIZACION Y REMIELINIZACION Y SU POTENCIAL TERAPEUTICO EN TRASTORNOS NEUROLOGICOS

PID2019-109724RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clemastine induces an impairment in developmental myelination

  • Palma, Ana
  • Chara, Juan Carlos
  • Montilla, Alejandro
  • Otxoa de Amezaga, Amaia
  • Ruíz-Jaén, Francisca
  • Planas, Anna M.
  • Matute, Carlos
  • Pérez-Samartín, Alberto
  • Domercq, María
Abnormalities in myelination are associated to behavioral and cognitive dysfunction in neurodevelopmental psychiatric disorders. Thus, therapies to promote or accelerate myelination could potentially ameliorate symptoms in autism. Clemastine, a histamine H1 antagonist with anticholinergic properties against muscarinic M1 receptor, is the most promising drug with promyelinating properties. Clemastine penetrates the blood brain barrier efficiently and promotes remyelination in different animal models of neurodegeneration including multiple sclerosis, ischemia and Alzheimer’s disease. However, its role in myelination during development is unknown. We showed that clemastine treatment during development increased oligodendrocyte differentiation in both white and gray matter. However, despite the increase in the number of oligodendrocytes, conduction velocity of myelinated fibers of corpus callosum decreased in clemastine treated mice. Confocal and electron microscopy showed a reduction in the number of myelinated axons and nodes of Ranvier and a reduction of myelin thickness in corpus callosum. To understand the mechanisms leading to myelin formation impairment in the presence of an excess of myelinating oligodendrocytes, we focused on microglial cells that also express muscarinic M1 receptors. Importantly, the population of CD11c+ microglia cells, necessary for myelination, as well as the levels of insulin growth factor-1 decrease in clemastine-treated mice. Altogether, these data suggest that clemastine impact on myelin development is more complex than previously thought and could be dependent on microglia-oligodendrocyte crosstalk. Further studies are needed to clarify the role of microglia cells on developmental myelination., This work was supported by Spanish Ministry of Education and Science (SAF 2016-75292- R); Spanish Ministry of Science and Innovation (PID 2019-109724RB-I00); Basque Government (PI-2016-1-0016); the University of the Basque Country (UPV/EHU); and Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED; grant CB06/05/0076). AP has a predoctoral fellowship from the University of the Basque Country (UPV/EHU), AM has a predoctoral fellowship from the Spanish Ministry of Education and Science and AO-de-A has a postdoctoral fellowship from the Basque Government., Peer reviewed